Lymphocyte Subpopulations in Melanoma Patients Treated with Dendritic Cell Vaccines
The main goal of cancer immunotherapy is to induce or boost tumor-specific effector cells able to eliminate or reduce tumor progression. In this study, we characterized lymphocyte phenotypes in melanoma patients receiving dendritic cell (DC)-based vaccinotherapy. We found that several biological markers served as unfavorable prognostic factors for patients’ response to therapy. This included decrease of CD4+ and CD8+ lymphocyte levels, 10% and higher increase of CD16+CD3+CD8+ lymphocyte population, and increase of CD16+CD8+perforin+T lymphocytes, especially in combination with decreased levels of CD16+CD8-perforin+ and CD8+CD16-perforin+ cells. Increase in CD8+CD16-perforin+ T lymphocytes with normal levels of CD16+CD8-perforin+ cells and the absence of CD16+CD8+perforin+ and regulatory lymphocytes were shown to be the positive prognostic markers for patients’ response to DC vaccines.
KeywordsDendritic Cell Natural Killer Cell Melanoma Patient Lymphocyte Subpopulation Dendritic Cell Vaccine
Unable to display preview. Download preview PDF.
- Kadagidze, Z.G., Chertkova, A.I. and Slavina, E.G. (2006) Immunoregulatory CD25+CD4+ cells. Russ. Biother. J., 7, 13–21.Google Scholar